martes, 20 de enero de 2026

Corvus pill shows promise in early-stage eczema trial The company plans to advance its therapy in the competitive field

https://www.statnews.com/2026/01/20/corvus-pill-eczema-study-soquelitinib-dupixent/ By Adam FeuersteinJan. 20, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

No hay comentarios:

Publicar un comentario